<DOC>
	<DOC>NCT03058406</DOC>
	<brief_summary>The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.</brief_summary>
	<brief_title>A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Participants with soft tissue sarcoma who will receive eribulin mesylate per the approved indication in routine clinical practice None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sarcoma, Soft Tissue</keyword>
	<keyword>Halaven Injection</keyword>
	<keyword>E7389</keyword>
</DOC>